Caribou Biosciences Inc (CRBU)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.44-6.49%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
Caribou Biosciences leads in CRISPR gene editing with a strong pipeline. The company aims to fund operations into 2H 2027, ensuring stability. Dose expansion for CB-011 could unlock future growth. Recent earnings beats show some operational progress.
Caribou is still loss-making with negative EPS expected through 2027. Revenue growth is uncertain despite high analyst expectations. Litigation and recent selloff highlight risks. Funding beyond 2H 2027 is not yet secured.
The price is about 27% above our fair value near $1.48, reflecting nearly 95% expected revenue growth. Our view is cautious as consensus expects growth that may not materialize given current losses and risks.
Breaks if: Dose expansion for CB-011 stalls or is halted
Continue dose expansion for CB-011 as part of the operating plan.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making, and while management is stable, recent performance has weakened, indicating a challenging environment ahead.
The market appears to have priced in a low level of fragility, with a justified valuation despite the company's losses. There is a notable expectations gap, suggesting that investors are cautious about future performance.
Fundamentally, CRBU is likely to continue facing challenges due to ongoing cash burn and mixed progress on key clinical trials. Management's focus on maintaining a funding runway into 2027 is critical, but near-term risks remain elevated.
The long-term thesis hinges on the outcomes of pivotal clinical trials and the broader healthcare sector's performance. Key factors include guidance changes and the impact of economic conditions on the healthcare sector.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The reason to own CRBU has diminished as its financial performance dropped. This change moved it from the robust half to the weak half of its sector. The latest earnings beat did not offset this decline in standing.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Cash runway falls short of funding operations into 2H 2027
Ensure cash, cash equivalents, and marketable securities are sufficient to fund the operating plan into the second half of 2027.
Breaks if: Revenue growth falls below 70% YoY in FY 2027
Over the next 1 to 3 years, CRBU's trajectory will depend on trial advancements and market conditions. Not investment advice.